| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802325801014 | 232580101 | INTEGRILIN INJ.SO.INF 0.75MG/ML VIALX100ML | 35.14 | 36.86 | 50.80 |
| 05/2018 | 2802325802011 | 232580201 | INTEGRILIN INJ.SOL 2MG/ML VIALX10ML | 11.17 | 11.71 | 16.13 |
For treatment of myocardial infarction and acute coronary syndrome.
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.
Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis)
Approximately 2.5 hours
* 55 mL/kg/h [patients with coronary artery disease]